To investigate the clinical efficacy and safety of atorvastatin calcium tablets in patients with type 2 diabetes cardiomyopathy.

Patients with type 2 diabetic cardiomyopathy admitted to our hospital were divided into treatment group and control group according to the treatment methods. The control group received conventional therapy, while the treatment group was administered atorvastatin calcium tablets at 20 mg·d^-1, orally for 4 weeks. The heart function, blood lipids, blood glucose, autophagy-related proteins and the relative expression levels of phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway-related mRNA were compared between the two groups, along with a safety evaluation.

A total of 198 patients were included, with 104 in treatment group and 94 in control group. After 4 weeks of treatment, the total clinical effective rate of treatment group was 92.31% (96 cases/104 cases), significantly higher than control group’s 80.85% (76 cases/94 cases) (P<0.05). After treatment, the left ventricular end diastolic diameter of treatment group and control group were (54.41±3.87) and (58.62±3.44) mm, respectively; the left ventricular end diastolic volume were (115.63±8.06) and (121.53±9.88) mL, respectively; the left ventricular end systolic diameter were (30.34±3.52) and (34.84±3.46) mm, respectively; the left ventricular end systolic volume were (69.72±6.32) and (76.57±6.24) mL, respectively; the left ventricular ejection fraction were (52.30±5.53)% and (48.52±4.21)%, respectively; the total cholesterol were (4.48±1.32) and (5.92±1.76) mmol·L^-1, respectively; triglycerides were (1.75±0.52) and (2.38±0.57) mmol·L^-1, respectively; low-density lipoprotein cholesterol were (2.49±0.65) and (3.32±1.21) mmol·L^-1, respectively; high-density lipoprotein cholesterol were (1.02±0.26) and (0.80±0.21) mmol·L^-1, respectively; the levels of benzyl chloride 1 were (3.28±0.43) and (2.62±0.41) ng·mL^-1, respectively; the levels of autophagy related gene 7 were (6.38±1.07) and (4.60±0.86) ng· mL^-1, respectively; the relative expression levels of PI3K mRNA were 0.68±0.25 and 0.94±0.28, respectively; the relative expression levels of Akt mRNA were 0.58±0.27 and 0.95±0.30, respectively; the relative expression levels of mTOR mRNA were 0.66±0.31 and 0.98±0.32, respectively. The above indicators in treatment group were statistically significant compared with control group (all P<0.05). The adverse drug reactions in treatment group include liver dysfunction, gastrointestinal reactions and muscle pain; the control group had abnormal liver function and gastrointestinal reactions. The total incidence of adverse drug reactions in treatment group was 5.77% (6 cases/104 cases), while in control group was 3.19% (3 cases/94 cases). There was no statistically significant difference between the two groups (all P>0.05).

Atorvastatin tablets can significantly improve cardiac structure and function, and regulate blood lipid levels in patients with type 2 diabetic cardiomyopathy. Additionally, it exerts cardioprotective effects by promoting autophagosome formation and downregulating the activity of the PI3K/Akt/mTOR pathway.